Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SHR-1316 + SHR-2002 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SHR-1316 | SHR 1316|SHR1316|Adebrelimab|HTI 1088|HTI-1088|HTI1088 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | SHR-1316 is a monoclonal antibody that targets PD-L1 (CD274), potentially resulting in antitumor activity (PMID: 33760397). | |
SHR-2002 | SHR2002|SHR 2002 | Limited information is currently available on SHR-2002 (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05082545 | Phase I | SHR-1316 + SHR-2002 | Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors | Completed | AUS | 0 |